AM Best Revises Outlooks to Stable for California Insurance Company and Affiliates
The ratings reflect NAC's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, limited business profile and marginal enterprise risk management (ERM).
The revised outlooks reflect improved governance at the company. In prior cycles, the group experienced delayed financial audits. Management strengthened the company's financial reporting team and reconstituted the board of directors to address many of the governance issues. The company's 2024 audits were completed in advance of their deadline, and the assignment of a more-prominent auditor was communicated to AM Best. While the group's protracted legal dispute over a conservatorship order is ongoing, the potential adverse financial consequences can be viewed as immaterial at this point in time. AM Best will continue to monitor the situation and respond if necessary.
The FSRs of A- (Excellent) and the Long-Term ICRs of "a-" (Excellent) have been affirmed with outlooks revised to stable from negative for the following affiliates of California Insurance Company, which are collectively referred to as NAC:
American Atlantic Assurance Co. Ltd.
Continental Indemnity Company
Florida Casualty Insurance Company
Illinois Insurance Company
Oklahoma Property and Casualty Insurance Company
Pennsylvania Insurance Company
Texas Insurance Company
This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.
Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805544382/en/
Contacts
Dan Hofmeister, CPA, FRM, CAIA Associate Director +1 908 882 1893 dan.hofmeister@ambest.com
Steven M. Chirico, CPA Director +1 908 882 1694 steven.chirico@ambest.com
Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 christopher.sharkey@ambest.com
Al Slavin Senior Public Relations Specialist +1 908 882 2318 al.slavin@ambest.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Trump Wildly Claims Wall Street Journal And China Are In Cahoots Amid Epstein Lawsuit
President Donald Trump alleged in a bizarre rant that The Wall Street Journal wants to see China 'WIN, BABY, WIN' on Thursday. 'The reason that The Wall Street Journal Editorial Board is always negative on 'TRUMP,' and the Hundreds of Billions of Dollars we're bringing into our Country through Tariffs, numbers that the U.S.A. has never seen before, is because they are China centric or, at a minimum, Globalists, and they would rather see China and the World, for reasons unknown, 'WIN, BABY, WIN,' the POTUS wrote in a Truth Social post. Trump then insisted that if 'the United States were not able to charge Tariffs to other Countries, it would be Economically defenseless and, of no further force or effect. The only thing that can destroy our Country are Crooked, Radical Left Judges, of which there are many!' The president has faced scrutiny over his sweeping global tariffs, which went into effect Thursday, subsequently raising the prices of household goods for Americans. The tariffs are projected to affect imports from more than 60 countries. The WSJ — which has grilled the president's efforts during his second term in office — and Trump have been embroiled in an ongoing feud. The dispute ignited further after the outlet published a report about an alleged, racy birthday cardthat Trump sent to convicted sex offender and disgraced financier Jeffrey Epstein in 2003. The letter was said to contain a drawing of a naked woman and a strange message about secrets, according to the WSJ. Trump, who is suing the WSJ over its report on the letter, has denied writing the letter. 'I never wrote a picture in my life. I don't draw pictures of women,' he told the Journal. 'It's not my language. It's not my words.' The president added: 'I'm gonna sue The Wall Street Journal just like I sued everyone else.' Trump further slammed the WSJ over their report in a separate Truth Social post, calling the article a 'false, malicious, and defamatory story.' Related... Trump Fires Back At Reporters Over 'Bulls**t' Epstein Question Trump Lashes Out At 'Racist Sleazebag' Charlamagne Tha God After Epstein-MAGA Comment Trump's Sleight-Of-Hand On The Jeffrey Epstein Scandal
Yahoo
18 minutes ago
- Yahoo
Meta selects PIMCO, Blue Owl for $29 billion data center financing, Bloomberg News reports
(Reuters) -Meta has selected investment management firm PIMCO and alternative asset manager Blue Owl Capital for a $29 billion financing deal related to its data center projects in rural Louisiana, Bloomberg News reported on Thursday. Reuters could not immediately verify the report.


Bloomberg
18 minutes ago
- Bloomberg
Medical Tech Firm Heartflow Prices $317 Million IPO Above Range
Heartflow Inc. raised $317 million in its initial public offering, pricing shares above the top of a marketed range. The company, which is an artificial intelligence software platform focused on heart disease, sold 16.67 million shares at $19 each, according to a statement Thursday.